Loading
A phase 1/2 trial of Rilvegostomig in melanoma and non-small-cell lung cancer, run by AstraZeneca, now recruiting.
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07115043 by AstraZeneca, with 120 participants planned, started 2025-07-29 and due to reach its primary completion in 2029-10-02. Interventions recorded: AZD6750, rilvegostomig. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/